MaxCyte shares plunge after Rockville biotech firm sharply lowers 2023 revenue outook


The company is significantly less bullish about revenue growth than it was a few months ago.

Previous Change at the top of Schneider Downs' wealth management arm
Next Report: Despite price increases, Jax housing market still ranks high for affordability